白介素17与系统性红斑狼疮发生发展相关的研究进展  

Research progress of interleukin 17 in the occurrence and development of Systemic Lupus Erythematosus

作　　者：孔迪 邓丹琪[1] KONG Di;DENG Danqi(Department of Dermatology and Venereology,Second Affiliated Hospital of Kunming Medical University,Kunming 650101,China)

机构地区：[1]昆明医科大学第二附属医院皮肤性病科,云南昆明650101

出　　处：《皮肤病与性病》2023年第5期303-306,共4页Dermatology and Venereology

基　　金：国家自然科学基金(82160595)。

摘　　要：近年来生物制剂已广泛用于各类皮肤病的治疗,原理在于可以阻断参与疾病发生的特定细胞因子来达到治疗疾病的目的。系统性红斑狼疮为一种累及多系统会危及生命的自身免疫性疾病,白细胞介素17(IL-17)为狼疮发病核心过程的关键介质,开发一种针对IL-17的精准治疗方案无疑能使患者获益。本文将从IL-17与系统性红斑狼疮(SLE)的关系、抗IL-17疗法等方面进行综述,旨在为IL-17作为SLE治疗的靶点提供理论指导。In recent years,biologics have been widely used in the treatment of various dermatological diseases,based on the principle that specific cytokines involved in disease development can be blocked for the purpose of treating the disease.SLE is a highly destructive autoimmune disease,and interleukin 17(Interleukin-17,IL-17)is a key mediator in the core process of lupus pathogenesis.Developing a precise therapeutic regimen targeting IL-17 will undoubtedly benefit patients.This article will review the relationship between IL-17 and SLE,and anti-IL-17 therapy,aiming to provide theoretical guidance for IL-17 as a target for SLE treatment.

关 键 词：系统性红斑狼疮 白细胞介素17 治疗靶点 

分 类 号：R593.241[医药卫生—内科学]